Business
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
Potentially pivotal GBM study evaluating lead program, Berubicin, enrollment completed; Topline data expected in the first half of 2025Recent strategic
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Potentially pivotal GBM study evaluating lead program, Berubicin, enrollment completed; Topline data expected in the first half of 2025Recent strategic in-license of TPI 287 is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBMCompany plans to engage the U.S. FDA to seek guidance on advancing TPI 287 into a potential registration study for recurrent GBMCompany committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure HOUSTON, TX / ACCESSWIRE / August 15, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the second quarter 2024 ended June 30, 2024.\"It has been an important year for CNS Pharmaceuticals with completion of enrollment in our Berubicin trial, and more recently, our in-licensing of a highly synergistic asset for development, TPI 287. As we look to the remainder of the year, we are executing on the path towards our planned topline results for our Berubicin trial, which we expect in the first half of next year and engaging the U.S. FDA to seek guidance on advancing TPI 287 into a potential registration study for recurrent GBM. We are poised for a catalytic 2025 with some value-driving milestones expected across our pipeline. Our mission and vision remain firm; bring a meaningful treatment option to GBM patients and practitioners, as well as value to all stakeholders,\" commented John Climaco, Chief Executive Officer of CNS Pharmaceuticals.Clinical Development ProgressBerubicin: Innovative, first-in-class anthracycline that appears to cross the blood brain barrier and kill tumor cells currently being evaluated in a potentially pivotal trial is a multicenter, open-label, randomized and controlled study in adult patients with recurrent glioblastoma multiforme (WHO Grade IV) after failure of standard first-line therapy.As previously announced in April 2024, the Company completed enrollment with 252 patients in its global potentially pivotal study evaluating Berubicin for the treatment of GBM. In December 2023 the Company a...